Please login to the form below

Deal Watch table for June 2014

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers agreed during June 2014.

For an indepth analysis of these deals, read 'Pharma deals during June 2014'

Licensor acquired / licensee acquirer	Deal type	Product / technology	Headline ($m)
Covidien/ Medtronic	Company acquisition	Medical device company adding US critical mass	42,900
Idenix Pharmaceuticals/ Merck & Co	Company acquisition	Hepatitis C assets include IDX21437 (p1/2 nucleotide inhibitor) to combine with Merck HCV drugs	3,850
Labrys Biologics/ Teva	Company acquisition	Includes Labrys' p2b anti-CGRP mAb for treatment of episodic migraine	825
Chelsea Therapeutics/ Lundbeck	Company acquisition	Includes Northera (droxidopa) for neurogenic orthostatic hypotension (approved)	658
OAO Veropharm/ Abbott Laboratories	Company acquisition	Russian based manufacturing company	630
DAVA Pharmaceuticals/ Endo International	Company acquisition	Generics business including generic Doxycycline and Cefdinir	575
Bionomics/ Merck & Co	Exclusive research and licence agreement	BNC 375 in Alzheimer's disease (preclinical)	526
Adaptimmune/ GSK	Co-development and option	TCR engineered T-cells which target NY-ESO-1 and other targets in oncology (p1/2)	350
Genia Technologies/ Roche	Company acquisition	Single molecule, semiconductor, DNA sequencing using nanopore technology	350
Medreich/ Meiji Seika	Company acquisition	India-based manufacturing company	290
Cellectis/ Pfizer	Collaboration	Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies directed at multiple selected oncology targets (platform)	265* + $28m equity
Dimension Therapeutics/ Bayer	Licence	Gene therapy for the treatment of haemophilia A (preclinical)	252
Synairgen/ AstraZeneca	Exclusive global licence	SNG 001 inhaled beta interferon (p2)	232
Ligand Pharmaceuticals/ TG Therapeutics	Exclusive global licence	Development, commercialisation of Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) inhibitors (preclinical)	208
Pregenen/ bluebird bio	Company acquisition	Gene editing technology platform	156
OraSure Technologies/ AbbVie	Co-promotion**	ODM-201, an investigational novel oral androgen receptor inhibitor (p2)	75
Orion/ Bayer	Co-development, option to co-promote in Europe	OraQuick HCV rapid test in US	68
Sorrento Therapeutics / Morphotek	Research and option agreement	To generate chemotherapeutic antibody drug conjugates (ADCs) (platform)	50
NanoString Technologies/ Celgene	Development	Development of a companion diagnostic assay	45
ECR Pharmaceuticals / Valeant	Company acquisition	Akorn subsidiary with branded generics business	41

All deals are worldwide unless otherwise noted.
* Deal terms included up to $185m milestones per product; estimated headline could be approximately $2.8bn if all products are successful.
**US only

The Deal Watch table is compiled by Medius Associates

9th July 2014